Anixa biosciences stock.

Nov 27, 2023 · Anixa Biosciences, Inc. is a biotechnology company. The Company is primarily engaged in developing vaccines and therapies that are focused on critical unmet needs in oncology and infectious disease. The Company's segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Others. A. While ratings are subjective and will change, the latest Anixa Biosciences ( ANIX) rating was a reiterated with a price target of $0.00 to $12.00. The current price Anixa Biosciences ( ANIX) is ...Track Anixa Biosciences Inc (ANIX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get ...Dec 1, 2023 · According to the issued ratings of 2 analysts in the last year, the consensus rating for Anixa Biosciences stock is Buy based on the current 2 buy ratings for ANIX. The average twelve-month price prediction for Anixa Biosciences is $10.50 with a high price target of $12.00 and a low price target of $9.00. Learn more on ANIX's analyst rating ... Stock Information. Quote; Charts; Historical Data; Analyst Coverage. ... Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr ...

Mar 23, 2021 · SAN JOSE, Calif., March 22, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa" or the "Company"), a biotechnology company focused on the treatment and prevention of cancer and ... When Anixa Biosciences last reported its balance sheet in January 2023, it had zero debt and cash worth US$28m. Importantly, its cash burn was US$7.3m over the trailing twelve months. So it had a ...Dec 1, 2023 · Earnings for Anixa Biosciences are expected to decrease in the coming year, from ($0.32) to ($0.37) per share. Anixa Biosciences has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, January 3rd, 2024 based off prior year's report dates. Read More.

Oct 23, 2023. Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board

SAN JOSE, Calif. and STUTTGART, Germany, Jan. 24, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and ...Sep 28, 2018 · SAN JOSE, Calif., Sept. 28, 2018 /PRNewswire/ -- ITUS Corporation (the "Company") (NASDAQ: ITUS ), a biotechnology company focused on using the body's immune system to fight cancer, today ... Get Anixa Biosciences Inc (ANIX.PH) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsAnixa Biosciences stock has received a consensus rating of buy. The average rating score is and is based on 12 buy ratings, 0 hold ratings, and 0 sell ratings. What was the 52-week low for Anixa ...

SAN JOSE, Calif., Aug. 23, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced ...

May 22, 2023 · SAN JOSE, Calif., May 22, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that, in ...

Anixa Biosciences, Inc. is a biotechnology company. The Company is primarily engaged in developing vaccines and therapies that are focused on critical unmet needs in oncology and infectious disease. The Company's segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Others.When Anixa Biosciences last reported its balance sheet in January 2023, it had zero debt and cash worth US$28m. Importantly, its cash burn was US$7.3m over the trailing twelve months. So it had a ...SAN JOSE, Calif., July 20, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that due to public health and safety concerns related to the ongoing COVID-19 global pandemic and to support the health and well-being of its …SAN JOSE, Calif., Aug. 31, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today ...Anixa Biosciences, Inc. is a biotechnology company. The Company is primarily engaged in developing vaccines and therapies that are focused on critical unmet needs in oncology and infectious disease. The Company's segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Others.Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the U.S. Patent and ...

About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T ...SAN JOSE, Calif., Aug. 7, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ...SAN JOSE, Calif., April 28, 2022 /PRNewswire/ --Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today ...First patient in breast cancer vaccine trial shares her experience. Fox Carolina. October 6, 2023.Introduction. For many decades, the primary approaches to cancer treatment were surgery, chemotherapy, and radiation therapy. Better targeted therapies such as monoclonal antibodies and other small molecule and biological drugs have been developed over the last 25 years. More recently the exciting field known as immunotherapy has enabled the ...

A high-level overview of Anixa Biosciences, Inc. (ANIX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Stock analysis for Anixa Biosciences Inc (ITUS:US) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Dec 1, 2023 · See the latest Anixa Biosciences Inc stock price (ANIX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Oct 23, 2023. Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory BoardStock Price Forecast. According to 2 stock analysts, the average 12-month stock price forecast for ANIX stock stock is $10.5, which predicts an increase of 210.65%. The lowest target is $9.00 and the highest is $12. On average, analysts rate ANIX stock stock as a strong buy.The high in the last 52 weeks of Anixa Biosciences stock was 6.45. According to the current price, Anixa Biosciences is 51.94% away from the 52-week …Amit Kumar. https://www.anixa.com. Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company’s therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell ...About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine …

Dec 1, 2023 · According to the issued ratings of 2 analysts in the last year, the consensus rating for Anixa Biosciences stock is Buy based on the current 2 buy ratings for ANIX. The average twelve-month price prediction for Anixa Biosciences is $10.50 with a high price target of $12.00 and a low price target of $9.00. Learn more on ANIX's analyst rating ...

According to 6 analyst offering 12-month price targets in the last 3 months, Anixa Biosciences has an average price target of $10.83 with a high of $12.00 and a low of $9.00.

Phone Number 6315495974. Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer ...ANIXA BIOSCIENCES INC (ANIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its partner, Cleveland Clinic ...Anixa Biosciences Inc stock performance at a glance. Check Anixa Biosciences Inc’s past financial performance, like revenue or net income, plus the top level summary of its …According to 6 analyst offering 12-month price targets in the last 3 months, Anixa Biosciences has an average price target of $11.0 with a high of $12.00 and a low of $9.00.SAN JOSE, Calif., Aug. 28, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ('Anixa' or the 'Company') (NASDAQ: ANIX), a biotechnology company focused...Company to present on its ongoing Phase 1 ovarian cancer CAR-T trial. SAN JOSE, Calif., Oct. 31, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will present at the Ovarian Cancer National …Stock Price Forecast. According to 2 stock analysts, the average 12-month stock price forecast for ANIX stock stock is $10.5, which predicts an increase of 210.65%. The lowest target is $9.00 and the highest is $12. On average, analysts rate ANIX stock stock as a strong buy.Firm. Analyst. Chardan. Matthew Barcus, Ph.D. H.C. Wainwright & Co. Yi Chen, Ph.D. Raghuram Selvaraju, Ph.D. Anixa Biosciences, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Anixa Biosciences, Inc.'s performance made by these analysts are theirs alone and do not represent …2 analysts have issued twelve-month target prices for Anixa Biosciences' stock. Their ANIX share price targets range from $9.00 to $12.00. On average, they …

SAN JOSE, Calif., April 17, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer today announced that Cleveland Clinic presented the most up-to-date data from the Phase 1 Trial of its breast cancer vaccine. The data presented showed that in the …The upgrade of ANIXA BIOSCIENCES INC to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the ...The latest price target for Anixa Biosciences ( NASDAQ: ANIX) was reported by HC Wainwright & Co. on Tuesday, August 29, 2023. The analyst firm set a price target for 12.00 expecting ANIX to rise ...Nov 30, 2023 · View ANIXA BIOSCIENCES INC ANIX investment & stock information. Get the latest ANIXA BIOSCIENCES INC ANIX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Instagram:https://instagram. best oil and gas etfsapphire pkbest industries to invest in long termbarrons advisor Barcus covers the Healthcare sector, focusing on stocks such as Anixa Biosciences, uniQure, and Purple Biotech. According to TipRanks , Barcus has an average return of -1.2% and a 41.94% success ... nasdaq wraphomebuilders etf short Nov 28, 2023 · In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Anixa Biosciences (ANIX – Research Report), with a price target of $12.00. Yi Chen has given Anixa Biosciences ... Oct 23, 2023. Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board realty income dividen Oct 23, 2023. Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory BoardSep 12, 2023 · Anixa Biosciences Incorporated (NASDAQ:ANIX) is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. ANIX stock is worth $3.39 and is down 20% YTD. ANIX stock ...